exenatide vs tirzepatide (a GLP-1 receptor agonist) rapidly lowered intracranial pressure in active IIH, with a sustained signal at 12 weeks and no meaningful weight change. The authors suggest an ICP-lowering Beyond glycemia: Comparing tirzepatide to

Understanding your genetic predispositions helps your provider select the best GLP-1 medication and starting dose to minimize side effects like sulfur burps from the outset

For the anti-obesity medication (AOM) cohort, patients who had one or more pharmacy claims for Zepbound or Wegovy between 1 November 2023, and 31 December 2023, were identified (identification period)

doi: 10.1016/j.cmet.2012.06.015 31 AlhadeffALBairdJ-PSwickJCHayesMRGrillHJ

However, this result relied entirely on unadjusted data, was driven largely by a single large cohort, and lacked detail on specific malformation subtypes, limiting how much can be concluded from it